Key Points
- CEO Ian Mortimer sold 270,000 shares on March 9 at an average of $60.33 for about $16.29M, cutting his ownership by roughly 97.8% to 6,000 shares (SEC filing).
- Xenon priced an upsized public offering to raise roughly $650M at $57/share, which substantially boosts the balance sheet to fund Phase 3 and commercial work but increases dilution risk.
- Phase 3 efficacy readout: azetukalner met its goal in the focal-onset seizures study (X-TOLE2), with management aiming for an NDA filing in Q3 2026 and prompting several analyst price-target upgrades.
Xenon Pharmaceuticals Inc. (NASDAQ:XENE - Get Free Report) insider Andrea Difabio sold 2,607 shares of the business's stock in a transaction dated Tuesday, March 10th. The stock was sold at an average price of $60.11, for a total transaction of $156,706.77. Following the completion of the transaction, the insider directly owned 4,893 shares in the company, valued at $294,118.23. This trade represents a 34.76% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link.
Xenon Pharmaceuticals Stock Down 1.2%
NASDAQ XENE traded down $0.72 during trading hours on Thursday, reaching $58.33. 295,435 shares of the company were exchanged, compared to its average volume of 1,320,158. The stock has a market capitalization of $4.85 billion, a P/E ratio of -13.30 and a beta of 0.91. Xenon Pharmaceuticals Inc. has a 1 year low of $26.74 and a 1 year high of $63.95. The business's 50 day simple moving average is $43.23 and its 200-day simple moving average is $41.69.
Xenon Pharmaceuticals (NASDAQ:XENE - Get Free Report) last released its earnings results on Thursday, February 26th. The biopharmaceutical company reported ($1.31) earnings per share for the quarter, missing analysts' consensus estimates of ($1.20) by ($0.11). During the same quarter in the previous year, the firm posted ($0.84) EPS. As a group, sell-side analysts anticipate that Xenon Pharmaceuticals Inc. will post -3.1 earnings per share for the current year.
Institutional Investors Weigh In On Xenon Pharmaceuticals
A number of hedge funds and other institutional investors have recently bought and sold shares of XENE. Cinctive Capital Management LP boosted its holdings in shares of Xenon Pharmaceuticals by 1.1% in the fourth quarter. Cinctive Capital Management LP now owns 23,317 shares of the biopharmaceutical company's stock worth $1,045,000 after acquiring an additional 263 shares during the period. Arizona State Retirement System raised its stake in shares of Xenon Pharmaceuticals by 1.8% during the 3rd quarter. Arizona State Retirement System now owns 19,290 shares of the biopharmaceutical company's stock valued at $774,000 after purchasing an additional 334 shares during the period. State of Wyoming raised its stake in shares of Xenon Pharmaceuticals by 30.4% during the 4th quarter. State of Wyoming now owns 1,501 shares of the biopharmaceutical company's stock valued at $67,000 after purchasing an additional 350 shares during the period. Quarry LP lifted its holdings in Xenon Pharmaceuticals by 25.0% during the 3rd quarter. Quarry LP now owns 2,500 shares of the biopharmaceutical company's stock worth $100,000 after purchasing an additional 500 shares in the last quarter. Finally, Altfest L J & Co. Inc. lifted its holdings in Xenon Pharmaceuticals by 6.5% during the 4th quarter. Altfest L J & Co. Inc. now owns 8,232 shares of the biopharmaceutical company's stock worth $369,000 after purchasing an additional 501 shares in the last quarter. Institutional investors own 95.45% of the company's stock.
Trending Headlines about Xenon Pharmaceuticals
Here are the key news stories impacting Xenon Pharmaceuticals this week:
- Positive Sentiment: Phase 3 efficacy readout — Xenon’s azetukalner met its goal in the focal-onset seizures study (X-TOLE2), and management plans an NDA filing in Q3 2026, materially derisking the lead program and supporting near-term commercial value. Zacks: Azetukalner Study
- Positive Sentiment: Major capital raise — Xenon priced an upsized offering to raise roughly $650M at $57.00/share (with an underwriter option to add shares), which substantially strengthens the balance sheet to fund Phase 3/commercial work and reduces near-term financing risk. GlobeNewswire: Offering
- Positive Sentiment: Analyst optimism and higher price targets — Several firms boosted targets and reiterated buys (Deutsche Bank to $90, HC Wainwright to $74, Wells Fargo to $68, Needham bullish), which can drive buying interest and momentum. Deutsche Bank PT HC Wainwright Note
- Neutral Sentiment: HC Wainwright updated multi-year EPS forecasts (improving FY2028–FY2030 but nudging FY2027 slightly worse); the revisions show evolving model assumptions tied to program timing and commercialization, but remain estimates that can change with trial/regulatory developments. HC Wainwright EPS Revision
- Negative Sentiment: Insider selling — CEO Ian Mortimer and other insiders disclosed large open-market sales (Mortimer sold ~270k shares and others sold several thousand), substantially reducing insider ownership and potentially signaling liquidity-taking or governance concerns for some investors. SEC Filing: Insider Sales
- Negative Sentiment: Dilution risk — while the $650M raise boosts runway, the sizable share issuance (and potential additional underwriter option) increases outstanding shares and may pressure near-term per-share metrics. GlobeNewswire: Offering
Analysts Set New Price Targets
Several brokerages have weighed in on XENE. Bank of America reissued a "buy" rating on shares of Xenon Pharmaceuticals in a report on Monday. Wells Fargo & Company boosted their target price on Xenon Pharmaceuticals from $49.00 to $68.00 and gave the company an "overweight" rating in a research note on Tuesday. Needham & Company LLC upped their price target on Xenon Pharmaceuticals from $58.00 to $80.00 and gave the company a "buy" rating in a research report on Monday. Morgan Stanley set a $97.00 price target on Xenon Pharmaceuticals in a research note on Monday. Finally, Guggenheim reissued a "buy" rating and issued a $90.00 price objective on shares of Xenon Pharmaceuticals in a report on Monday. Two research analysts have rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and one has issued a Sell rating to the company. According to MarketBeat.com, Xenon Pharmaceuticals presently has an average rating of "Buy" and a consensus price target of $71.94.
View Our Latest Research Report on Xenon Pharmaceuticals
About Xenon Pharmaceuticals
(
Get Free Report)
Xenon Pharmaceuticals Inc is a clinical‐stage biopharmaceutical company dedicated to discovering and developing novel, small‐molecule drugs targeting ion channels in the central and peripheral nervous system. The company's research focus centers on neurological and pain disorders—including epilepsy, migraine, and neuropathic pain—by modulating key ion‐channel proteins to restore normal neuronal function. Xenon's scientific platform draws upon advances in ion‐channel biology and structure‐based drug design to identify and optimize therapeutic candidates with the potential for improved safety and efficacy profiles compared with existing treatments.
The company's pipeline comprises multiple preclinical and clinical programs.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
